167 related articles for article (PubMed ID: 15671565)
1. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
Yang W; Barth RF; Wu G; Kawabata S; Sferra TJ; Bandyopadhyaya AK; Tjarks W; Ferketich AK; Moeschberger ML; Binns PJ; Riley KJ; Coderre JA; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
Clin Cancer Res; 2006 Jun; 12(12):3792-802. PubMed ID: 16778107
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
[TBL] [Abstract][Full Text] [Related]
4. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
[TBL] [Abstract][Full Text] [Related]
5. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
9. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
[TBL] [Abstract][Full Text] [Related]
10. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.
Yang W; Barth RF; Wu G; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Binns PJ; Riley K; Patel H; Coderre JA; Ciesielski MJ; Fenstermaker RA
Appl Radiat Isot; 2004 Nov; 61(5):981-5. PubMed ID: 15308179
[TBL] [Abstract][Full Text] [Related]
11. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
12. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.
Barth RF; Wu G; Yang W; Binns PJ; Riley KJ; Patel H; Coderre JA; Tjarks W; Bandyopadhyaya AK; Thirumamagal BT; Ciesielski MJ; Fenstermaker RA
Appl Radiat Isot; 2004 Nov; 61(5):899-903. PubMed ID: 15308165
[TBL] [Abstract][Full Text] [Related]
13. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.
Yang W; Barth RF; Wu G; Huo T; Tjarks W; Ciesielski M; Fenstermaker RA; Ross BD; Wikstrand CJ; Riley KJ; Binns PJ
J Neurooncol; 2009 Dec; 95(3):355-365. PubMed ID: 19588228
[TBL] [Abstract][Full Text] [Related]
14. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.
Paul DB; Barth RF; Yang W; Shen GH; Kim J; Triozzi PL
Gene Ther; 2000 Jun; 7(12):993-9. PubMed ID: 10871746
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
[TBL] [Abstract][Full Text] [Related]
16. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.
Yang W; Barth RF; Leveille R; Adams DM; Ciesielski M; Fenstermaker RA; Capala J
J Neurooncol; 2001 Oct; 55(1):19-28. PubMed ID: 11804279
[TBL] [Abstract][Full Text] [Related]
18. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
Clavreul A; Delhaye M; Jadaud E; Menei P
J Neurooncol; 2006 Aug; 79(1):9-17. PubMed ID: 16575532
[TBL] [Abstract][Full Text] [Related]
19. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids.
Grill J; Van Beusechem VW; Van Der Valk P; Dirven CM; Leonhart A; Pherai DS; Haisma HJ; Pinedo HM; Curiel DT; Gerritsen WR
Clin Cancer Res; 2001 Mar; 7(3):641-50. PubMed ID: 11297260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
